Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [QUIET] · [HEALTH]
4 clusters · 22 sources · 37 days · First seen · Last updated
Upadacitinib expanded approval for skin and arthritis
Overview
Clinical trials for the Janus kinase (JAK) inhibitor upadacitinib have demonstrated success in treating severe alopecia areata by blocking inflammatory signals via the JAK/STAT pathway. Research indicates that up to 23 percent of patients achieved complete scalp hair regrowth within six months, while approximately half achieved at least 80 percent regrowth.
Following these developments, the European Commission has approved new indications for upadacitinib to treat three immune-mediated diseases. This authorization includes severe alopecia areata and non-segmental vitiligo for adults and adolescents aged 12 and older. Additionally, the approval extends to active polyarticular juvenile idiopathic arthritis for patients from two years of age who have shown inadequate response or intolerance to disease-modifying antirheumatic drugs.
The approval for non-segmental vitiligo is based on Phase III Viti-Up clinical trials, which showed that a 15 mg daily dose achieved significant skin repigmentation compared to a placebo after 48 weeks. This makes upadacitinib the first authorized systemic treatment for non-segmental vitiligo within the European Union.
While these expansions address what Antonio Costanzo, Vice President of Sidemast, described as a “high patient demand,” specific availability in Italy remains subject to approval from the Italian Medicines Agency (AIFA).
Entities
AbbVie · upadacitinib · JAMA Dermatology · Harvard University · AIFA
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 3 SOURCES] Upadacitinib has been approved for the treatment of both vitiligo and alopecia areata on the same day.
- [● 3 SOURCES] In vitiligo, the drug blocks attacks on melanocytes to allow skin repopulation with pigment-producing cells.
- [● 3 SOURCES] The availability of the treatment in Italy depends on approval from the Italian Medicines Agency (AIFA).
Timeline
-
[HEALTH] 2 sourcesEuropean Commission approves upadacitinib for three immune-mediated diseases
The European Commission has approved upadacitinib for treating severe alopecia areata, non-segmental vitiligo, and active polyarticular juvenile idiopathic arthritis.
-
[HEALTH] 13 sourcesUpadacitinib approved for vitiligo and alopecia areata
Upadacitinib has been approved for treating vitiligo and alopecia areata by blocking inflammatory signals in the immune system to promote hair regrowth and skin repigmentation.
-
[HEALTH] 3 sourcesUpadacitinib shows effectiveness in treating severe alopecia areata
Upadacitinib, an arthritis drug, shows high efficacy in treating severe alopecia areata, with some clinical trial participants regaining full hair regrowth within 24 weeks.
-
[HEALTH] 4 sourcesUpadacitinib shows significant hair regrowth in severe alopecia areata trials
Clinical trials for the arthritis drug upadacitinib (Rinvoq) showed that up to 23 percent of severe alopecia areata patients achieved complete scalp hair regrowth within six months.
Sources
adnKronos.com · cagliarilivetv.it · canaledieci.it · chiny24.com · diariodecadiz.es · huelvainformacion.es · ilpais.it · ilrestodelcarlino.it · ilsannioquotidiano.it · intelligentliving.co · interestingengineering.com · laragione.eu · livornotoday.it · newsbytesapp.com · notizie.it · polityka.co.pl · quotidianodelsud.it · quotidianodibari.it · savutoweb.it · scinexx.de · stabianews.it · tech.wp.pl
This summary has been updated 2 times: see revision history